healthcare sector in india monthly update august 2012

7/29/2019 Healthcare Sector in India Monthly Update August 2012

http://slidepdf.com/reader/full/healthcare-sector-in-india-monthly-update-august-2012 1/14

Healthcare Sector in India

Monthly Update

August 2012



Top Story

Aurobindo Pharma and Glenmark to set their footprint in US market

The US FDA has lent approval for manufacturing and marketing of generic version of montelukast sodium tablets to Aurobindo Pharma and Glenmark. The companies are already

finalizing distribution of asthma and allergies related drug in US market. Aurobindo Pharma

has been granted approval for marketing of montelukast sodium tablets of 10mg strength

nd chewable version of 4mg and 5mg strength. Glenmark on the other hand has beena

granted abbreviated new drug approval (ANDA) for the 10mg strength tablet.

The aforementioned drug is the generic version of Merck & Co's Singulair tablets that is

prescribed for asthma, allergic rhinitis and prophylaxis. The launch of generic version of the

drug can benefit US patients by the cost curtailment that generics offer.

News Update

General

Cognosys launches CogHMS solution

Cognosys Technologies has recently launched the BI version of its Hospital Management

Premier Suite named as CogHMS in India. The hospital information system has been

designed for integrating hospital chains and related wellness centres integrate seamlessly.

The CogHMS has been developed by IBM Certified Healthcare Software Sales Professionals

team from Cognosys and has been certified by Microsoft Azure and HP ConvergenceInfrastructure Cloud. The software has been built keeping in mind the rapid progress that is

taking place in the IT world as it can be accessed from a single browser through tablets, self

service kiosks and is equipped with biometric recognition and electronic medical record

(EMR).

It can help in powerful integration of all the essential departments of the hospital that

comprises of not only in‐house pharmacy, canteen, laundry, blood bank, financial transaction

but also 3rd party insurance providers. Installation of the software help will help in

drastically reducing cost of operation through its Software as a Service (SaaS) solution and

making hospital operation and patient care more robust.

Cipla to establish 3 new API manufacturing plants

Mumbai based Cipla Ltd. is in plans to invest INR 5 bn for establishing active pharmaceutical

ingredients (API) manufacturing facilities at Patalganga and Kurkumbh districts in

Maharashtra and at Bengaluru in Karnataka. Cipla expects completion of establishment of

facilities by 2012‐13. Cipla’s sole intension of setting up API manufacturing plants is

s

pecifically because of acceptance of its several dosage forms by US FDA and WHO.

Healthcare Sector – Monthly Update



Cipla has been earning a major share of its revenue from international markets that is driving

Cipla to focus on the products demanded in international markets.

Neiss Wellness

captures

marketing

rights

of

My

Wish

Hub

in

India

The London based nutraceutical company My Wish Hub (MWH) will foray into Indian market

through Mumbai based Neiss Wellness India Ltd. Neiss Wellness has been endowed with the

responsibility of preparation and implementation of marketing strategies and generation of

distribution network for MWH products.

MWH primarily deals in over‐the‐counter (OTC) products, nutritional supplements as well as

cosmetics.

Apollo taking initiative to strengthen its owner label product portfolio

Apollo Hospitals Enterprise is focusing at raising its number of owner label products in its

retail pharmacy business segment. The enterprise has over 200 private label products and isset to augment its product portfolio by increasing its nutraceutical segment product base. By

trengthening its pharmacy retail product base Apollo is targeting to enhance its totals

pharmacy sales from current 4% to 10% in 3‐4 years time.

rivate labels draw a comparatively higher profit margin which is encouraging retailers and

uper market operators to take initiative in scaling up sale of private label products.

P

s

Gujarat attracting investments from major healthcare companies

US based Abott Laboratories is in plans of establishing a manufacturing plant at Jhagadia in

ujarat. The manufacturing plant will cater to manufacture of its neutraceutical range of

P

G

products that comprises of brands like Ensure and ediaSure.

The company has already acquired 45 acres of land and will be set up with an initial

investment of INR 3.6 bn. With establishment of the Gujarat plant it will be the second

neutraceutical manufacturing plant apart from the one located at Mumbai in Maharashtra.

Gujarat has been attracting investments from various healthcare companies – Israel based

Teva Pharmaceutical Industries in collaboration with US based Procter & Gamble has

nvested INR 5bn. Scotland based Mark Dolan and Singapore based Biosensors International

re among other key investors.

i

a

Religare to launch IPO

Religare Healthcare Trust will launch an initial public offering (IPO) of INR 22 bn inSingapore that will help Indian hospital group Fortis Healthcare to reduce its debt level. The

premarketing of the IPO is expected to be initiated in Sep 2012. The IPO will be offering a

minimum yield of 8.5% to its investors that are being structured as a business trust. Fortis

Group is also considering the launch of IPO for its Indian diagnostic business SRL Diagnostics

Ltd.




Fortis Group has registered a consolidated net debt of INR 62.37bn as on Jun 2012 and in an

ffort to improve the company’s leverage ratios; the conversion from private to public

nterprise has been chalked out as the best possible solution.

e

e

Wockhardt acquires FDA approval for Felodipine

Mumbai based Wockhardt Ltd. has earned approval from the Food and Drug Association

(FDA) for its generic blood pressure drug. Wockhardt formulated felodipine which is the

generic version of AstraZeneca high blood pressure drug named Plendil. The tablets will be

ade available at 2.5 mg, 5 mg and 10 mg strengths. Having gained the approval, Wockhardt m

plans to launch the drug immediately.

he FDA approval for the hypertension drug will open a huge market base for Wockhardt

hat can reap sizeable revenue for the company.

T

t

News Update

Regulatory Clinical trials to be made compulsory for traditional drugs

The department of Ayush (Ayurveda, Unani, Siddha and Homeopathy) has raised the

proposal of establishing two separate drug controller generals for allopathic and traditional

medicines. A proposal has been raised to make clinical trials mandatory for all new

traditional medicines that will cater to only the new patented drugs.

The rising export of AYUSH and herbal products and lack of any formal protocol on detection

of safety standards of traditional drugs has led the department of Ayush to keep a tab on

standard of ASU drugs. The implementation of clinical trials for traditional Ayurveda, Siddha

and Unani medicines will mark the wider acceptance of these medications.

New Drugs Advisory Committee rolls out permit for clinical trial proposal

The newly formed expert advisory committee New Drugs Advisory Committee of Vaccine

operating under Drug Controller General of India (DCGI) has rolled out permission for

conducting Phase I clinical trial to vaccination proposals. The committee has permitted

clinical trial application of diphtheria, tetanus; acellular pertussis (DTaP) vaccines to Pune

based Serum Institute of India.

The consent from the committee has been granted under the condition to submit the data for

the patients to be enrolled for the clinical trial for the committee’s satisfactory evaluation.

PCMC and MUHS join hands for establishment of medical institute

The Pimpri Chinchwad Municipal Corporation (PCMC) and Maharashtra University of Health

Sciences (MUHS) have joined hands to establish a post graduate medical institute. The




institute will be established at Yashwantrao Chavan Memorial Hospital (YCMH) at Pimpri in

Maharashtra.

The setting up of the institute comes under the 'Vision 2030 ‐ health and medical services inPimpri Chinchwad.' A MoU draft will be conceived by the participants shortly that will be

sent to civic body for required modifications and will go into the approval table on Sep 11,

2012.

India aids Sri Lanka

The Indian government is assisting the Sri Lankan government in setting up a 200 bedded

ward complex at Vavuniya District Hospital that will cater to the needs of indoor patients of

Vavuniya and its adjoining districts. The Indian government will be providing full grant

assistance by payment of INR 200 mn for establishment of the unit. It is being implemented

y joint effort of the Health Ministry and the Northern Province Indigenous Medicineb

Ministry that is expected to start operation post Feb 2014.

The proposal for the unit was submitted by the Health and Indigenous Medicine through the

External Resources Department in Feb 2012. Apart from Vavuniya District Hospital, India

has also aided Sri Lankan town of Dickoya in construction of 150 bedded hospital by

providing a grant of INR 1.2 bn that is expected to initiate operation by Apr 2013. The

development partnership between India and Sri Lanka for assistance in improvement of Sri

Lanka’s health sector is proving beneficial for the island neighbor of India.

News Update

Expansion Plans Stempeutron to mark its launch in 2015

Bangalore based Stempeutics Research Pvt. Ltd. is expected to launch its product

Stempeutron by mid 2015. Stempeutron is currently undergoing phase II clinical trial for

indication of critical limb ischemia (CLI), osteoarthritis (OA) and liver sclerosis. On receipt of

learance of phase II clinical trial the drug that is expected to be issued in 6 months, it willc

enter phase III trial by early 2013.

he clinical trial has enrolled patients on a pan India basis with 126 patients registered forLI and 60 patients each for OA and liver sclerosis.TC

The Mission Hospital Group to enter Ranchi

Durgapur based The Mission Hospital (TMH) is in plans of investing INR 1 bn in setting up a

200 bedded super specialty hospital at Tupudana Industrial Area in Ranchi. The Jharkhand

government will provide 3.7 acres plot on a long term lease basis for 30 years followed by




renewal for the same period. The lease will be granted by the Ranchi Industrial Area

Development Authority (RAIDA).

The project will come up as a public private partnership (PPP) between the TMH and theharkhand government. TMH already has presence in Durgapur, Asansol, Siliguri and

angtok – and with this hospital it shall be able to expand its network to Jharkhand too.

J

G

Royapettah Hospital to set up cancer unit

Chennai located Government Royapettah Hospital will establish a cancer treatment centre

that is estimated to be worth INR 170 mn. The state government of Tamil Nadu under the

aegis of Chief Minister J Jayalalithaa has decided to sanction a grant worth INR 99.3 mn. The

mount allocated by the state government will be directed towards the purchase of newa

medical equipments and creation of 83 medical and para‐medical vacancies.

The establishment of cancer unit in the government hospital will be beneficial for the underprivileged population section as the chief minister has directed for the expansion of the

ealm of "Chief Minister's Comprehensive Health Insurance Scheme" to include members

egistered under the Farmers' Protection Scheme.

r

r

Pluristem Therapeutics to conduct clinical trial in India

The Indian Ministry of Health has granted permission for conducting Phase II clinical trial to

the Israel based therapeutics company Pluristem Therapeutics Ltd. The company will be

carrying out clinical trial for placental expanded cells for treatment of Buerger's disease.

Buerger's disease causes blockage of blood vessels of the hands and feet. The successful

ompletion of Phase II trial will be followed up by a multi‐national Phase III trial in USA,c

Europe and India.

The rare but common disease in India that affects 45%‐63% of patients suffering from

eripheral artery disease will find a solution that currently has no remedy. The urgent need

or a certified treatment has led the Indian Health Ministry to give nod for the clinical trial.

p

f

S3V Vascular Technologies increasing its number of manufacturing plants

Bangalore based S3V Vascular Technologies Pvt. Ltd. will initiate operation of a new

anufacturing plant at Bangalore by end of 2012. The company has made an investment of m

INR 14 bn for initiation of this manufacturing plant.

The company is also in plans of expanding its medical devices product line for which it iseyeing location at Vishakhapatnam to set up a facility by 2014. It aims to develop futuristic

products in fields of intervention cardiology, neurology, peripheral and endovascular

reatments. The product line would include catheters, disposables and other devices used in

arious angiographic procedures in radiology and cardiology.

t

v




Cipla pacts with Aspen Pharmacare

Mumbai based Cipla has signed a pact with South Africa based Aspen Pharmacare for

arketing its products in Australia. Cipla partnered with the supplier of branded and genericm

pharmaceuticals company Aspen as it has a marketing network in over 100 countries.

Cipla would be developing the generic products that Aspen would be marketing in Australia.

he deal was struck after Aspen’s recent acquisition of Australian drug maker Sigma

harmaceuticals’s OTC and pharmaceutical divisions.

T

P

Mylan forays into India market

USA based Mylan Pharmaceuticals has initiated its Indian operations and will be focusing

especially on HIV/AIDS drugs for now. The company will be launching 18 antiretroviral

rugs in Indian market. Aiming to provide quality medication to the huge population the

ompany has decided to initiate marketing of its broad portfolio of antiretroviral drugs.

d

c

Moolchand Healthcare in expansion spree

Moolchand Healthcare Pvt. Ltd. is in plans of expanding its base through acquisitions. The

company has set aside INR 5 bn for acquisition of hospital chains, in‐vitro fertilization (IVF)

clinics and pathological laboratories. The healthcare institute has tied up with private equity

firm Sequoia Capital for funding the expansion. The enterprise will invest about INR 2 bn on

uyout of IVF clinics, INR 50 bn for lab acquisitions with INR 1 bn being funded by Sequoiab

Capital and the remaining from internal accruals and debt.

The expansion programme will be initiated with hospitals in the northern and eastern parts

f India and for IVF clinics and pathological labs expansion will be targeted in tier II and tier

II towns and cities.

o

I

Industry Expert Speak

Gujarat attracting investments from major healthcare companies - Ankit Suri, Associate Vice President, Tecnova India

"A foreign company looks at state government's investment friendly policies, labor

availability and customer base in the region. Gujarat is a perfect destination for foreign

pharma companies as the state offers single‐window approval, low cost of land, skilled labor

and is a hub for pharma and generic medicines.”

Pluristem Therapeutics to conduct clinical trial in India - Zami Aberman, Chairman, President and CEO "The information gathered in this trial will be a valuable step towards our goal of

successfully developing a PLX cell‐based product for the treatment of the entire spectrum of

peripheral vascular diseases."




Transaction Detail (Jun – Aug 2012)

Date Buyer Target Deal Size

(INR mn)

% stake Deal Status Type

of

Transaction

2 g3rd Au

2012

India

Innovation

Fund

&

Indian Angel

Network

Consure

MedicalN.A. N.A. Completed Private Equity

21st Aug

2012

India Equity

PartnersAxiss Dental N.A. N.A. Planned Private Equity

13th Aug

2012

Somerset Indus

Capital

Partners

Express Clinics

Pvt. Ltd.N.A. N.A. Completed Private Equity

13th Aug

2012

Goldman Sachs

&

New Enterprise

Associates

Nova Medical

Centres2969.35 N.A. Completed Private Equity

13th Aug

2012

Sun

Pharmaceutical

Industries Ltd.

Taro

Pharmaceutical

Industries

32,552.9 34% Planned M&A

30th Jul

2012Sequoia Capital

Practo

Technologies

Pvt. Ltd.

250 N.A. Completed Private Equity

23rd Jul

2012

Signet

Healthcare

Partners

Claris

Lifesciences227.6 2.20 Completed Private Equity

19th

Jul2012

Medtronic Inc. TrivitronHealthcare

5498.70 N.A. Planned Private Equity

13th Jul

2012

Evolvence India

Life Sciences

Fund

Dr. Agarwal's

Healthcare600 25 Completed Private Equity




4th Jul

2012

Rajasthan

Venture Capital

Fund

International

Oncology

Services Pvt.

Ltd.

200 N.A. Completed Private Equity

14th Jun

2012

Jacob Ballas

Capital

&

IFC

Super Religare

Laboratories

(Fortis

Healthcare)

3700 N.A. Planned Private Equity

Annual Financial Results – Revenue (INR mn) – Major Healthcare

Companies

Companies FY ’09 FY ’10 FY ’11 FY’ 12

Biocon Ltd. 16,492.50 23,932.70 27,947.70 21,483.0

Blue Star Ltd. 25,026.2 25,249.7 29,536.8 27,888.5

Cadila Healthcare Ltd. 29,066.00 35,780.00 44,671.00 50,899.7

Cipla Ltd. 52,876.20 56,704.00 63,850.70 68,477.0

Dabur India Ltd. 28,122.40 33,958.00 40,817.40 52,832.0

Dr. Reddy’s Laboratories

(DRL)69,441.00 70,277.00 74,693.00 96,737.4

GlaxosmithKline

Consumer Heathcare Ltd.19,757.6 23,693.3 27,688.6 28,857.3

Glenmark

Pharmaceuticals Ltd.21,241.20 25,291.30 29,490.70 40,206.4

Jubilant life Sciences Ltd. 35,491.00 38,047.80 34,484.40 42,539.5

Lupin Ltd. 38,508.30 48,318.10 57,851.90 70,829.1

Nestle India Ltd. 51,395.5 62,609.4 74,994.6 77,409.0

Opto Circuits (India) Ltd. 8,185.197 10,775.826 15,855.631 23,568.543

Piramal Healthcare Ltd. 32,478.20 36,276.30 25,157.70 20,838.3

Ranbaxy Laboratories

Ltd.75,970.40 89,607.70 101,614.1 117,153.2




Siemens India Ltd. 93,070.2 96,272.4 119,718.1 124,657.9

Strides Arcolab Ltd. 13,101.6 16,958.4 25,245.2 25,645.1

Sun Pharmaceuticals

Industries Ltd.42,723.00 38,086.30 57,214.30 80,056.6

Torrent Pharmaceuticals

Ltd.16,306.60 19,160.40 22,264.80 26,959.2

Wockhardt Ltd. 3,6294.4* 36,477.60 37,633.50 46,138.0

Annual Financial Results – Income (INR mn) - Major Healthcare

Companies

Companies F Y ’09 FY ’10 FY ’11 FY’ 12

Biocon Ltd. 931.2 2,932.40 3,675.20 3,384.0

Blue Star Ltd. 1,802.9 2,114.9 1,609.6 ‐1,051.0

Cadila Healthcare Ltd. 3,031.00 5,051.00 7,110.00 6,525.9

Cipla Ltd. 7,710.20 10,825.90 9,895.70 11,442.4

Dabur India Ltd. 3,905.00 5,010.80 5,685.70 6,449.0


(DRL)‐5,168.00 1,068.00 11,040.00 14,262.1

Glaxosmithkline Consumer

Healthcare Ltd.2,327.8 2,998.5 3,552.1 3,765.6

Glenmark Pharmaceuticals

Ltd.1,916.60 3,244.70 4,532.10 4,603.5

Jubilant life Sciences Ltd. 2,831.80 4,214.60 2,297.20 145.6

Lupin Ltd. 5,015.40 6,816.30 8,625.50 8,676.5

Nestle India Ltd. 6,550.0 8,186.6 9,615.5 9,815.7




Opto Circuits (India) Ltd. 2,087.3 2,603.0 3,672.5 5,718.8

Piramal Healthcare Ltd. 3,162.50 4,819.00 128,833.60 1,115.0

Ranbaxy Laboratories Ltd. 2,964.90 14,967.50 ‐28,997.3 ‐19,573.5

Siemens India Ltd. 7,046.0 7,577.7 8,677.5 7,300.6

Strides Arcolab Ltd. 1,096.80 1,224.50 2,244.8 8,258.4

Sun Pharmaceuticals

Industries Ltd.

18,177.30 13,510.80 18,160.60 25,872.5

Torrent Pharmaceuticals Ltd. 1,843.70 2,312.00 2,701.70 2,840.4

Wockhardt Ltd. ‐4,355.4* ‐9,804.20 905.2 3,427.1

Quarterly Financial Results – Revenue (INR mn) – Major Healthcare

Companies

Companies

Jul-Sep

2011

Oct -Dec

2011

Jan-Mar

2012

Apr-Jun

2012

Biocon Ltd. 5,084.40 5,171.90 5,892.2 N.A.

Blue Star Ltd. N.A. 5,896.9 N.A. N.A.

Cadila Healthcare Ltd. 12 0,196.4 13,524.60 14 .9,633 N.A.

Cipla Ltd. N.A. 17,580.00 N.A N.A.

Dabur India Ltd. 12,623.30 14,526.80 13,858.3 N.A.


(DRL)22,678.00 27,692.00 26,584.0 N.A.


Healthcare Ltd.7,200.7 6,854.0 8,608.7 7, 6869.


Ltd.10,554.50 10,310.90 10,751.2 N.A.




Jubilant life Sciences Ltd. 10,480.80 10,871.70 12,235.9 N.A.

Lupin Ltd. 17,416.6 17,917.0 20,063.7 N.A.

Nestle India Ltd. 19,631.00 19,633.2 20,558.7 19 .8,865

Opto Circuits (India) Ltd. 5,620.4 6,112.9 6,627.0 N.A.

Piramal Healthcare Ltd. 4,775.80 5,518.30 8,858.0 N.A.

Ranbaxy Laboratories Ltd. 20 .3,955 37 .1,923 36,954.0 31 .6,740

Siemens India Ltd. N.A. N.A. 37 2601.43 N.A.

Strides Arcolab Ltd 7,693.10 6,864.7 5,274.7 5, 9082.

Sun Pharmaceuticals

Industries Ltd.18,946.00 21,451.30 23,299.3 N.A.

Torrent Pharmaceuticals Ltd 6,833.3 6,965.9 6,686.8 N.A.

Wockhardt Ltd. 11,105.30 12,086.70 12,413.90 N.A.

Companies

Jul-Sep

2011

Oct -Dec

2011

Jan-Mar

2012

Apr-Jun

2012

Biocon Ltd. 857.0 848.50 978.0 N.A.

Blue Star Ltd. N.A. (327.6) N.A. N.A.

Cadila Healthcare Ltd. 1,0 026.8 1,492.10 1, 8708. N.A.

Cipla Ltd. N.A. 2,699.10 N.A. N.A.

Dabur India Ltd. 1,738.6 1,728.20 1,705.1 N.A.


(DRL)3,078.0 5,130.0 3,427.0 N.A.


Healthcare Ltd.1,030.3 591.0 1,319.7 1,066.0

Quarterly Financial Results – Income (INR mn) - Major Healthcare

Com anies





Ltd.558.6 461.20 1,482.7 N.A.

Jubilant life Sciences Ltd. 793.6 ‐783.90 ‐635.3 N.A.

Lupin Ltd. 2,668.70 2,350.60 1,556.4 N.A.

Nestle India 2,611.80 2,308.30 2,757.3 2, 7459.

Opto Circuits (India) Ltd. 1,210.6 1,250.8 2,093.5 N.A.

Piramal Healthcare Ltd. 524.3 85.2 ‐386.8 N.A.

Ranbaxy Laboratories Ltd. ‐4,645.8 ‐29 .7,827 12,467.6 ‐5,857.3

Siemens India Ltd. N.A. N.A. 3,040.0 N.A.

Strides Arcolab Ltd 464.7 684.1 6,420.7 904.8

Sun Pharmaceuticals

Industries Ltd.5,977.4 6,683.0 8202.1 N.A.

Torrent Pharmaceuticals Ltd 999.9 831.8 ‐16.5 N.A.

Wockhardt Ltd. 1,275.80 2,128.10 ‐1,916.4 N.A.

* denotes a change in financial year

Events Calendar

Healthcare Bihar 2012

Date: 1st Sep, 2012

Venue: Hotel Mau

Gandhi Mai

rya, Ashoka Banquet, South

Contact

dan at Patna

Contact 01

Person: Vijay Bhuller/ Dilip Kumar

Fax No. / +

No.: +91‐612‐6450301/+91‐612‐64503

: +91‐612‐2238572 91‐612‐2238572

Email: [email protected] / [email protected]

25th A nn ual Conference of The Indian Society

for Ath CON 2012 e

Date: 1

rosclerosis Research ISARst Sep – 3rd Sep, 2012

Venue: Chidambaram, Tamil Nadu

Website: annama n/biochem_conf laiuniversity.ac.i

sep12.htm Contact Person: P. Subramanian

2nd In n C onter ational onference Pediatrics &

Gynecology

Date: 24th Sep – 26th Sep, 2012

Venue: H

Centre, H

yderabad Marriott Hotel & Convention

yd

Website:

erabad

ww.omicsonline.org/w pediatrics2012/

Contact No.: +91‐40‐27522999


mailto:[email protected]












http://annamalaiuniversity.ac.in/biochem_confsep12.htm

















http://www.omicsonline.org/pediatrics2012/

















Research on India (ROI) is a leading source for market research on various sectors in India

hat offers premium research content from worldwide publishers of market researcht

reports.

Contact us:

mW: https://www.researchonindia.co

; International: +91 (33) 4027 6214/5T

E

: India (Toll Free): 1800 102 1133

: [email protected]

Connect with Us

Disclaimer: This

monthly

update

is

published

for

general

information

only

based

on

press

articles and company releases. Research on India has not independently verified any of information and is not responsible for any loss or damage arising from use of this document.


http://www.linkedin.com/groups?gid=3280715&trk=hb_side_g

https://twitter.com/ResearchOnIndia

http://www.facebook.com/researchonindia

healthcare sector in india monthly update august 2012

Documents